TFX (Teleflex) ROCE %: 1.43% (As of Mar. 2026)

What is Teleflex ROCE %?

Teleflex TFX +1.75% 76 ROCE % is 1.43% as of Mar. 2026. GuruFocus rates TFX with a GF Score™ of 76/100 and a GF Value™ of $179.56 (Modestly Undervalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Teleflex's annualized ROCE % for the quarter that ended in Mar. 2026 was 1.43%.

Teleflex (NYSE:TFX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Teleflex ROCE % Related Terms

Teleflex ROCE % Historical Data

* Premium members only.

The historical data trend for Teleflex's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teleflex ROCE % Chart

Teleflex Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

9.63

7.98

4.07

1.64

1.98

Teleflex Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															4.78	9.55	-23.65	14.88	1.43

76GF Score

Teleflex Inc TFX

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Teleflex ROCE % Calculation

Teleflex's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	124.776	/	( ( (7097.914 - 649.36)	+	(6947.239 - 762.026) )	/ 2 )
	=	124.776	/	( (6448.554	+	6185.213)	/ 2 )
	=	124.776	/	6316.8835
	=	1.98 %

Teleflex's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	87.564	/	( ( (6947.239 - 762.026)	+	(6783.002 - 728.049) )	/ 2 )
	=	87.564	/	( ( 6185.213	+	6054.953 )	/ 2 )
	=	87.564	/	6120.083
	=	1.43 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 1.43% mean?

Teleflex (TFX) has a ROCE % of 1.43% as of Mar. 2026.

Is Teleflex's ROCE % too high?

Teleflex's current ROCE % is 1.43%. The Medical Devices & Instruments industry median ROCE % is 2.23. Teleflex's value of 1.43% is 35.9% below this industry median. Overall, Teleflex has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Teleflex's ROCE % compare to AVTR and STVN?

Teleflex's ROCE % of 1.43% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Teleflex's value of 1.43% is 35.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teleflex's current ROCE % of 1.43% is 35.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teleflex's current ROCE % is 1.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Teleflex stock overvalued right now?

Based on GuruFocus' analysis, Teleflex (TFX) is currently considered Modestly Undervalued. The stock's GF Value™ is $179.56, compared to a current price of $128.72 — trading 28.3% below its estimated fair value. The current ROCE % is 1.43% and 35.9% below the Medical Devices & Instruments industry median of 2.23. Teleflex's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Teleflex (TFX), the current ROCE % is 1.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teleflex (TFX) Overvalued in 2026?

Based on GuruFocus' analysis, Teleflex stock appears to be undervalued. The current stock price of $128.72 is trading 28.3% below its estimated GF Value™ of $179.56. GuruFocus considers Teleflex to be Modestly Undervalued.

Key valuation signals for TFX:

ROCE %: 1.43%
GF Value™: $179.56 vs. price of $128.72 (28.3% below fair value)
GF Score™: 76/100 with 7 warning signs
Industry Position: 35.9% below the Medical Devices & Instruments median

No single metric tells the full story. See the TFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teleflex Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies AVTR STVN RGEN ATR NVST MMSI MMED ICUI WRBY LMAT ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Other Exchanges 1TFX:Italy TBH:Germany

Address 550 East Swedesford Road, Suite 400, Wayne, PA, USA, 19087

Website https://www.teleflex.com

Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.

76GF Score

Get the complete analysis for TFX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$128.72

Price

$179.56

GF Value

View TFX Analysis

See ROCE % data for all stocks →